Genetic Immunity Develops Unique Nanomedicine Formulation for DermaVir Therapeutic Vaccine for HIV/AIDS  
5/13/2010 9:03:57 AM

MCLEAN, Va. & BUDAPEST, Hungary--(BUSINESS WIRE)--Genetic Immunity, a multi-national biopharmaceutical company developing nanomedicine vaccines today announces publication of the Company’s innovative work to develop a stable liquid formulation to deliver a novel nanomedicine. Appearing in the International Journal of Pharmaceutics, the paper addresses how Genetic Immunity was able to overcome significant hurdles facing the field to successfully formulate the first topically administered nanomedicine therapeutic vaccine for the treatment of HIV/AIDS, DermaVir.